ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CDKN1B	1027	10389625	-	Down regulation/ Down expression	-	-	21 (n=12; proliferative phase; n=9; secretory phase)	41	-	-	Department of Gynaecopathology; University Hospital Eppendorf; Hamburg	IA (n=8); IB (n=21); IC (n=6); II (n=6)	1 (n=21); 2 (n=15); 3 (n=5)	[1] There is a strongly reduced or abolished expression of p27 in endometrial carcinoma (85.3% of cases). The 41 tumours analysed were classified according to p27 staining intensity and percentage of positive cells into the following categories of p27 expression: negative/very low (56.0%); low (29.3%); moderate (14.7%) and high (0.0%). [2] Comparison with the p53 status showed that all tumours with strong p53 expression had low/negative p27 staining; while those that were positive for p27 had negative/low p53 staining. [3] p27 expression is essential for the control of normal endometrial proliferation; and reduced or absent p27 expression may be an important step in endometrial carcinogenesis.	Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia	Virchows Archiv	434(5):423-8	1999
CDKN1B	1027	14614018	Endometrial Adenocarcinoma	Down regulation/ Down expression	-	Tumor suppressor	73 (30 normal endometrium+ 24 hyperplasia without atypia+ 5 atypical hyperplasia+ 14 cysic atrophy)	217	28 to 93	64	Department of Gynecology of the University of Florence and St Orsola Hospital; University of Bologna; Italy.	I (n=92); II (n=15); III (n=14); IV (n=3)	1 (n=46); 2 (n=49); 3 (n=21)	[1] p27 expression could progressively decrease from normal endometrium through hyperplastic endometrium to invasive endometrial carcinomas; suggesting that loss of this tumor suppressor may represent a novel and distinct molecular alteration involved in estrogen-related endometrial adenocarcinomas (type I). [2] A significant loss of p27 expression from normal (33%) through hyperplastic endometrium (50%) to endometrial adenocarcinomas (71%; P </= 0.001).	Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas	Clinical Cancer Research	9(14):5332-8	2003
CDKN1B	1027	15188025	Endometrial adenocarcinoma	Down regulation/ Down expression	-	-	30 normal functional (15 proliferative; 15 secretory)	38 endometrial carcinoma; 24 hyperplastic endometrium (12 without atypia; 12 with atypia)	35 to 65	-	Kocaeli University Medical Faculty Hospital	I (n=31); II (n=2); III (n=5)	1 (n=18);2 (n=14)3 (n=6)	[1] p27 is necessary to control the proliferation of endometrium and its loss of expression seems to play a role in some aspects of endometrial carcinogenesis.[2] Nuclear p53 expression was detected in 13 (34.2%) patients with endometrial carcinoma and was higher in non-endometrioid carcinomas and in tumors with increasing FIGO grade (p<0.05). [3] In complex hyperplasia with atypia; p27 expression was even higher and it was significantly reduced in the endometrial carcinoma group (p<0.05). [4] p27 expression was present both in the proliferative and secretory phases; the expression being stronger in the secretory period.	Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression)	Pathology Oncology Research	10(2):89-97	2004
CDKN1B	1027	21454826	-	Polymorphism	-	-	1212	1199	-	54.8 (Diseased); 54.88 (Control)	-	-	-	"[1] Polymorphisms of the CDKN1B gene may play a role in endometrial carcinogenesis. [2]Three single nucleotide polymorphisms in the CDKN1B gene (rs11055027	rs3759216	and rs34330) were related to endometrial cancer risk	although only the association with rs34330 remained statistically significant after adjustment for multiple comparisons. The odds ratios for rs34330 were 1.33 (95% confidence interval (CI): 1.06	2